Impact of Antimicrobial Stewardship Program Intervention Acceptance on Hospital Length of Stay.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY Hospital Pharmacy Pub Date : 2023-10-01 Epub Date: 2023-03-16 DOI:10.1177/00185787231160436
Daniel Hurtado, Mario Varela, Alejandra Juarez, Y-Nha Nguyen, Salin Nhean
{"title":"Impact of Antimicrobial Stewardship Program Intervention Acceptance on Hospital Length of Stay.","authors":"Daniel Hurtado, Mario Varela, Alejandra Juarez, Y-Nha Nguyen, Salin Nhean","doi":"10.1177/00185787231160436","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Inappropriate antibiotic use is a major public health concern. Excessive exposure to antibiotics results in the proliferation of multidrug-resistant bacteria, increase in potentially avoidable adverse drug reactions, healthcare utilization, and cost. Currently, systematic reviews and controlled trials assessing the effects of antimicrobial stewardship programs (ASP) on hospital length of stay (LOS), mortality, and cost-savings are conflicting. Some studies reported a significant cost-savings driven by shorter hospital LOS while the others found no effect and, in some cases, prolonged LOS. Shortening the time to appropriate therapy and reducing unnecessary days of therapy have been shown to reduce hospital LOS. <b>Objective:</b> The purpose of this study was to evaluate the effects of prescriber acceptance to ASP interventions on hospital LOS. <b>Methods:</b> Between January 2018 and December 2019, 764 charts were retrospectively reviewed for patients who received antimicrobial treatment and in whom an ASP intervention was performed. Patients were allocated into 2 groups: those whose ASP interventions were accepted and those whose were rejected. Provider responses were then documented within 24 hours of being communicated. The primary outcome was hospital LOS. Secondary outcomes included 30-day readmission rates and inpatient antimicrobial duration of therapy (DOT). <b>Results:</b> There were 384 patients with an accepted ASP intervention and 380 with a denied intervention. Baseline characteristics were similar between both groups, except for a difference in the types of intervention performed (<i>P</i> < 0.001). The median hospital LOS for patients in the accepted intervention group was 6.5 days compared to 7 days in the rejected intervention group (<i>P</i> = 0.009). Antimicrobial DOT was also shorter in the accepted intervention group (5 vs 7 days; <i>P</i> < 0.001). There was no difference in 30-day readmission rates (<i>P</i> = 0.98). <b>Conclusion:</b> Prescriber acceptance to ASP interventions decreases hospital LOS and antimicrobial DOT without affecting 30-day readmission rates.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":"58 5","pages":"491-495"},"PeriodicalIF":0.8000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498969/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787231160436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Inappropriate antibiotic use is a major public health concern. Excessive exposure to antibiotics results in the proliferation of multidrug-resistant bacteria, increase in potentially avoidable adverse drug reactions, healthcare utilization, and cost. Currently, systematic reviews and controlled trials assessing the effects of antimicrobial stewardship programs (ASP) on hospital length of stay (LOS), mortality, and cost-savings are conflicting. Some studies reported a significant cost-savings driven by shorter hospital LOS while the others found no effect and, in some cases, prolonged LOS. Shortening the time to appropriate therapy and reducing unnecessary days of therapy have been shown to reduce hospital LOS. Objective: The purpose of this study was to evaluate the effects of prescriber acceptance to ASP interventions on hospital LOS. Methods: Between January 2018 and December 2019, 764 charts were retrospectively reviewed for patients who received antimicrobial treatment and in whom an ASP intervention was performed. Patients were allocated into 2 groups: those whose ASP interventions were accepted and those whose were rejected. Provider responses were then documented within 24 hours of being communicated. The primary outcome was hospital LOS. Secondary outcomes included 30-day readmission rates and inpatient antimicrobial duration of therapy (DOT). Results: There were 384 patients with an accepted ASP intervention and 380 with a denied intervention. Baseline characteristics were similar between both groups, except for a difference in the types of intervention performed (P < 0.001). The median hospital LOS for patients in the accepted intervention group was 6.5 days compared to 7 days in the rejected intervention group (P = 0.009). Antimicrobial DOT was also shorter in the accepted intervention group (5 vs 7 days; P < 0.001). There was no difference in 30-day readmission rates (P = 0.98). Conclusion: Prescriber acceptance to ASP interventions decreases hospital LOS and antimicrobial DOT without affecting 30-day readmission rates.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗菌药物管理计划干预接受度对住院时间的影响。
背景:抗生素使用不当是一个主要的公共卫生问题。过度接触抗生素会导致耐多药细菌的增殖,增加潜在的可避免的药物不良反应、医疗保健利用率和成本。目前,评估抗菌药物管理计划(ASP)对住院时间(LOS)、死亡率和成本节约的影响的系统审查和对照试验是相互矛盾的。一些研究报告称,缩短医院服务水平可以显著节省成本,而其他研究则没有发现任何影响,在某些情况下,服务水平延长。缩短适当治疗的时间和减少不必要的治疗天数已被证明可以降低医院服务水平。目的:本研究旨在评估处方接受ASP干预对医院LOS的影响。方法:在2018年1月至2019年12月期间,对764名接受抗菌治疗并进行ASP干预的患者的图表进行回顾性审查。患者被分为两组:接受ASP干预的患者和拒绝ASP干预的人群。然后在24小时内记录提供者的回复 沟通的时间。主要结果是医院LOS。次要结果包括30天再次入院率和住院抗菌药物治疗持续时间(DOT)。结果:384名患者接受ASP干预,380名患者拒绝干预。除干预类型不同外,两组的基线特征相似(P P = 0.009)。接受干预组的抗菌剂DOT也较短(5比7 天;P P = 0.98)。结论:处方接受ASP干预降低了医院LOS和抗菌DOT,而不影响30天的再入院率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
期刊最新文献
Cefepime/Enmetazobactam. Impact of a Medication Reconciliation Improvement Package on Adherence to Medication Reconciliation Among Internal Medicine Physicians: A Quality Improvement Project in a Lower-Middle Income Country. Implementing Research Into Practice as a Clinical Based New Practitioner Pharmacist. Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease. Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1